1. Home
  2. Live Updates
  3. Nephronet clinical trials

Live Breaking News & Updates on Nephronet Clinical Trials

Stay updated with breaking news from Nephronet clinical trials. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

SEATTLE (BUSINESS WIRE) Apr 10, 2024 ....

United States , Buenos Aires , Distrito Federal , James Tumlin , Alpine Immune Sciences , Nephronet Clinical Trials Consortium , Buenos Aires Convention Center , Exchange Commission , Securities Exchange , Vertex Pharmaceuticals Incorporated , World Congress , Alpine Immune Sciences Inc , Immune Sciences , Clinically Meaningful , Iga Nephropathy , Business Wire , Highlights Include , Nephrology Late Breaking , Updated Results , Enhanced Dual , Poster Session , Late Breaking , Exhibition Hall , Main Foyer , Emory University School , Nephronet Clinical Trials ,

Early RUBY-3 Data Shows Promise for Povetacicept in Glomerulonephritis

Preliminary data from the open-label RUBY-3 trial were presented at the American Society of Nephrology Kidney Week 2023. ....

United States , Emory University School Of Medicine , James Tumlin , Jonathan Barratt , American Society Of Nephrology Kidney Week , University Of Leicester , Alpine Immune Sciences , Nephronet Clinical Trials Consortium , Georgia Nephrology , American Society , Nephrology Kidney Week , Emory University School , Nephronet Clinical Trials , Kidney Week , Immune Sciences , Mayer Professor , Renal Medicine , Enhanced Dual , Autoantibody Associated Glomerulonephritis , Paper Presented , Autoimmune Glomerulonephritis , Late Breaking Poster Session ,

Alpine Immune Sciences, Inc. Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis

Alpine Immune Sciences, Inc. announced that the Company presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking poster session at the American Society. ....

United States , James Tumlin , American Society Of Nephrology Kidney Week , Pennsylvania Convention Center , American Society Of Nephrology , Alpine Immune Sciences Inc , Nephronet Clinical Trials Consortium , Alpine Immune Sciences , American Society , Kidney Week , Enhanced Dual , Autoantibody Associated Glomerulonephritis , Poster Board Number , Late Breaking Posters Location , Exhibit Hall , Philadelphia Presenter , Emory University School , Chief Executive Officer , Nephronet Clinical Trials ,

Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

/PRNewswire/ Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that. ....

United States , Carl Spana , Jamesa Tumlin , Exchange Commission , Palatin Technologies Inc , Prnewswire Palatin Technologies Inc , Securities Exchange , Founder Of Nephronet Clinical Trials Consortium , Prospective Study , Reducing Urinary , Maintaining Podocyte Density , Nephronet Clinical Trials , Melanocortin Receptor Agonists , Securities Act , Securities Exchange Act , Palatin Technologies ,

Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease - read this article along with other careers information, tips and advice on BioSpace ....

United States , Carl Spana , Jamesa Tumlin , Exchange Commission , Palatin Technologies Inc , Securities Exchange , Founder Of Nephronet Clinical Trials Consortium , Palatin Technologies , Prospective Study , Reducing Urinary , Maintaining Podocyte Density , Nephronet Clinical Trials , Melanocortin Receptor Agonists , Securities Act , Securities Exchange Act ,